Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting during chemo: a new weapon against breast cancer?

NCT ID NCT07440784

Disease control Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study tests whether adding intermittent or water-only fasting to standard chemotherapy can improve outcomes for breast cancer patients. Sixty women will be split into four groups: chemo alone, chemo plus intermittent fasting, chemo plus intermittent fasting with a ketogenic diet, or chemo plus a two-week water-only fast. Researchers will measure tumor markers, immune cell counts, inflammation, and quality of life to see if fasting helps the body fight cancer better and handle treatment more easily.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intermittent fasting (23:1 regimen) and water-only fasting
What this could lead to
If it works, this could point toward a simple, low-cost way to boost chemotherapy effectiveness and reduce side effects for breast cancer patients.
What could go wrong
This is a small, early-phase trial with only 60 participants. Fasting may be hard to stick with, and results may not apply to all patients. It is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Aug 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 to 50 years * Histologically confirmed breast cancer (any TNM stage) * Currently receiving chemotherapy treatment at INOR, Abbottabad * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Body mass index (BMI) ≥ 24 kg/m² * Willing and able to provide written informed consent * Willing to comply with the assigned fasting and dietary interventions Exclusion Criteria: * Distant metastasis to liver or kidneys * ECOG performance status of 3 or 4 * Uncontrolled systemic diseases including cardiovascular disease, lung disease, or clinically confirmed metabolic disease * Human immunodeficiency virus (HIV) infection, chronic hepatitis B, hepatitis C, or other active infections clinically confirmed * Pregnant or lactating women * Concurrent participation in another interventional clinical trial * Inability to comply with fasting protocols due to medical or psychological reasons * Known contraindications to fasting including but not limited to eating disorders, severe malnutrition, or uncontrolled diabetes mellitus * Use of medications that may interfere with fasting or ketogenic diet (e.g., insulin, oral hypoglycemic agents requiring food intake) * Any condition that in the opinion of the investigator would compromise the safety of the participant or the integrity of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Intermittent Fasting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Institute of Nuclear Medicine Oncology & Radiotherapy (INOR)

    Abbottābād, Khyber Pakhtunkhwa, 22010, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.